Sanofi Tops Pfizer As Number One For Global Pharma Sales
08-Nov-2011
- United Kingdom
EvaluatePharma Ltd revealed that Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biotechnology specialist Genzyme predicted to help win its number one ranking.
“The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years,” commented Dr Jonathan de Pass, chief executive of EvaluatePharma. “Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest.”
| Market Rank
|
Rx & OTC pharma sales ($bn)
|
||||||||
| 2011 | 2012 | 2014 | 2016 | 2011 | 2012 | 2014 | 2016 | Annual growth
2011-16 |
|
| Sanofi | 3 | 1 | 1 | 1 | 47.9 | 51.6 | 55.4 | 58.4 | 4% |
| Novartis | 2 | 2 | 2 | 2 | 49.5 | 49.9 | 52.2 | 54.8 | 2% |
| Pfizer | 1 | 3 | 3 | 3 | 54.1 | 49.8 | 49.7 | 51.9 | (1%) |
| GlaxoSmithKline | 5 | 6 | 5 | 4 | 39.3 | 41.2 | 45.6 | 50.9 | 5% |
| Roche | 6 | 4 | 4 | 5 | 39.1 | 44.1 | 46.3 | 49.0 | 5% |
| Merck & Co | 4 | 5 | 6 | 6 | 42.1 | 41.9 | 41.4 | 43.4 | 1% |
| Johnson & Johnson | 8 | 8 | 7 | 7 | 24.8 | 26.5 | 29.4 | 31.5 | 5% |
| AstraZeneca | 7 | 7 | 8 | 8 | 32.0 | 29.2 | 27.5 | 25.7 | (4%) |
| Teva | 12 | 10 | 10 | 9 | 17.4 | 20.3 | 22.5 | 24.4 | 7% |
| Abbott Laboratories | 9 | 9 | 9 | 10 | 22.5 | 23.5 | 23.7 | 24.3 | 2% |
| Bayer | 11 | 12 | 11 | 11 | 18.9 | 19.7 | 21.7 | 23.4 | 4% |
| Takeda | 14 | 13 | 12 | 12 | 17.0 | 18.2 | 18.7 | 20.2 | 3% |
| Bristol-Myers Squibb | 13 | 16 | 17 | 13 | 17.1 | 14.2 | 15.4 | 18.9 | 2% |
| Novo Nordisk | 17 | 17 | 15 | 14 | 12.3 | 13.6 | 16.4 | 18.9 | 9% |
| Eli Lilly | 10 | 11 | 14 | 13 | 21.5 | 20.1 | 17.6 | 17.9 | (4%) |
Other news from the department business & finance
